RUBEN HERNAEZ to End Stage Liver Disease
This is a "connection" page, showing publications RUBEN HERNAEZ has written about End Stage Liver Disease.
Connection Strength
3.247
-
Using noninvasive clinical parameters to predict mortality and morbidity after cardiac interventions in patients with cirrhosis: A systematic review. Saudi J Gastroenterol. 2024 01 01; 30(1):14-22.
Score: 0.737
-
Serum testosterone levels and testosterone supplementation in cirrhosis: A systematic review. Liver Int. 2021 10; 41(10):2358-2370.
Score: 0.621
-
Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure". J Hepatol. 2021 02; 74(2):477.
Score: 0.600
-
Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure". J Hepatol. 2020 12; 73(6):1579-1580.
Score: 0.593
-
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis. Gut. 2023 12 07; 73(1):156-165.
Score: 0.185
-
Assessment of donor quality and risk of graft failure after liver transplantation: The ID2 EAL score. Am J Transplant. 2022 12; 22(12):2921-2930.
Score: 0.170
-
Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Intern Med. 2021 07 01; 181(7):949-959.
Score: 0.156
-
Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020 12; 73(6):1425-1433.
Score: 0.145
-
Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. Hepatology. 2021 12; 74(6):3316-3329.
Score: 0.040